What type of study is this?

September 10, 2025Pediatric Blood & CancerOpen Access

Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis demonstrates 77.8% overall response rate in relapsed/refractory B-ALL, indicating promising outcomes after CD19-CART.

Inotuzumab ozogamicin led to an overall response rate of 77.8% in pediatric B-ALL patients.
After treatment, 66.7% achieved measurable residual disease-negative remission, indicating effective therapy.
One-year event-free survival was 37.5%, reflecting the ongoing challenge of managing post-CD19-CART patients.
Adverse events like hepatotoxicity and prolonged cytopenias highlighted the need for careful monitoring during treatment.

Ogrodnik et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis demonstrates 77.8% overall response rate in relapsed/refractory B-ALL, indicating promising outcomes after CD19-CART.